Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05525741
Active, not recruiting Not applicable

Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients

NCT05525741 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire de Nice
Phase
Not applicable
Started
2022-10-19
Last updated
2024-12-04

Condition(s) studied

Skin and Connective Tissue Diseases

Investigational drug(s) / intervention(s)

Non segmental vitiligoHealth Volunteers

Non segmental vitiligo: The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit. The Investigator: * Inform the subject of the goals, constraints and risks of the study and obtain written consent. * Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including. If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.

Health Volunteers: The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit. The Investigator: * Inform the subject of the goals, constraints and risks of the study and obtain written consent. * Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including. If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.

Study summary

To compare the level of circulating functional mitochondria in the serum of vitiligo patients as compared to controls

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with non segmental vitiligo, * atopic dermatitis, psoriais, alopecia areata, * 1st degree relative of vitiligo patients. Exclusion Criteria: * segmental or mixed vitiligo, * personnal history of other autoimmune disorders, * oral use of antioxidant, * pregant women

Primary outcome measure(s)

  • Total number of circulating functionnal mitochondria (CFM) in the plasma — at baseline
    Level of CFM in vitiligo serum as compared to controls

Trial sites (1)

FacilityCityRegionStatus
CHU de Nice - Hôpital de l'Archet Nice Alpes-maritimes

More Centre Hospitalier Universitaire de Nice trials in France

AI-enhanced Imaging Analysis to Predict Post-EVAR Starting soon
Robotic Emergency General Surgery Program Starting soon
Comparison of Arterial and Capillary Blood Gas Analyses in Patients With Respiratory Distress Due to COPD or APE Recruiting
Videographic Feedback and Walk Rehabilitation in Post-Cerebrovascular Accident Recruiting
Home Based Personalized Training and Video Consultation in Mitochondrial Myopathies: Study of Efficacy and Tolerance. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05525741 on ClinicalTrials.gov ↗ ← All trials in France